The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024
Pfizer says that positive findings from two pivotal Phase III studies of investigational crisaborole topical ointment 2% (formerly AN2728) have been published in the online issue of the Journal of the American Academy of Dermatology. 14 July 2016
At its July meeting, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded a safety referral on one medicine, and initiated three new safety referrals. 11 July 2016
Anglo-Swedish drugmaker has entered into agreements with privately-held Danish drugmaker LEO Pharma that support its strategic focus on three main therapy areas; respiratory, inflammation and autoimmunity, cardiovascular and metabolic disease and oncology. 1 July 2016
Anglo-Swedish drugmaker AstraZeneca has terminated Valeant Pharmaceuticals’ right to develop and commercialize brodalumab in Europe, according to a statement. 1 July 2016
UK-based Sinclair Pharma has had some hugely challenging decisions to make as it has undergone a strategic review over the last 18 months. 25 June 2016
Cipher Pharmaceuticals (TSX: CPH) has licensed the rights to ASF-1096 (R-salbutamol) for use in anorectal disorders to fellow Canada-based Edesa Biotech. 22 June 2016
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness for England and Wales, has today published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the National Health Service. 22 June 2016
US biotech firm Regeneron Pharmaceuticals and French pharma major Sanofi have announced that their Phase III study of investigational dupilumab to treat adults with severe atopic dermatitis (AD) has met its primary and key secondary endpoints. 6 June 2016
Swedish dermatology specialist Lipidor and Cadila Pharmaceuticals, one of India’s largest privately-held pharma companies, have announced that they will collaborate on a Phase III trial and the joint commercialization of a psoriasis product. 1 June 2016
Almirall has signed, through its recently-acquired Dallas, USA-based subsidiary Thermigen, an exclusive US strategic marketing collaboration agreement for Silhouette Instalift with Sinclair Pharma, a UK specialty pharma company. 20 May 2016
Almirall and Bicosome, a start-up company that develops and commercializes high performance cosmetic and dermopharmaceutical ingredients, have entered into a research, collaboration and sublicense agreement. 19 May 2016
Almirall this morning released financials for the first quarter of 2016, showing that total revenues were down 7.5% at 201 million euros compared with the like 2015 period. 9 May 2016
UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has recommended US pharma major AbbVie’ Humira (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS). 6 May 2016
Stephen O’Hara is chief executive of OptiBiotix Health, a UK-based biotech which has been interesting big pharma recently with its Lactobacillus plantarum strain, a statin-free cholesterol pill. He spoke to the Pharma Letter... 4 May 2016
US pharma major Eli Lilly announced on Tuesday that the European Commission has granted marketing authorization for Taltz (ixekizumab) for plaque psoriasis. 26 April 2016
Allergan says it has acquired Topokine Therapeutics, a privately held, clinical-stage biotechnology company focused on developing topical medicines for fat reduction. 22 April 2016